Bulls Keep Del Fris...
Health Care: Drugs
Rigel Pharmaceuticals Inc. (RIGL: NASDAQ)
$4.74 -0.11 | -2.27%
05/17/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -98.84M | -85.97M | 37.89M | -111.55M |
| Operating Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 232.00K | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 141.00K | 153.00K | -1.75M | -2.83M |
| (Decrease) Increase In Other Current Liabilities | -1.00K | 674.00K | -4.39M | -96.00K |
| (Increase) Decrease In Other Working Capital | -150.00K | 610.00K | -2.78M | -4.11M |
| Other Non-Cash Items | 12.62M | 13.17M | 16.44M | 13.44M |
| Net Cash From Continuing Operations | -85.19M | -69.38M | 46.74M | -102.78M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -85.19M | -69.38M | 46.74M | -102.78M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 14.00K |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 439.72M | 415.49M | 216.25M | 0.00 |
| Purchases of Property, Plant & Equipment | -3.38M | -2.30M | -3.56M | -141.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -475.40M | -476.04M | -266.09M | -169.93M |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -39.05M | -62.85M | -53.40M | -30.66M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 139.09M | 142.78M | 1.96M | 103.60M |
| Repayment of Long-Term Debt | 0.00 | -800.00K | -1.14M | -1.45M |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 139.09M | 141.98M | 820.00K | 102.16M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 14.85M | 9.76M | -5.84M | -31.29M |
Portfolios with RIGL
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
Latest RIGL Headlines from TheStreet
- 5 Health Care Stocks Under $10 Ready to Rip Higher 04.18.13 | 09:04 pm
- 5 Stocks Poised for Breakouts 04.12.13 | 01:04 pm
- Frail Jobs Gains Gives Markets Jitters 04.05.13 | 04:04 pm
- Astra, Rigel Arthritis Pill Posts Mixed Trial Results 04.05.13 | 05:04 am
- 3 Stocks Under $10 Making Big Moves 03.15.13 | 07:03 am
- Stocks Under $10: Blossoming Biotech Play
09.25.12 | 06:09 am - The Next Big Thing in Biotech: Pfizer 05.04.12 | 06:05 am
- Biotech Calendar: Key Dates for October 10.03.11 | 08:10 am
- Vertex Arthritis Pill Shines in Mid-Stage Study 09.06.11 | 08:09 am
- Rigel Stock Falls On Unusually High Volume (RIGL) 05.26.11 | 10:05 am
Press Releases for RIGL
- Rigel Announces Participation At Two Investor Conferences - PR Newswire 02.28.13 | 07:02 am
- Rigel To Present At BIO CEO & Investor Conference - PR Newswire 02.07.13 | 07:02 am
- Rigel To Focus On Extensive Clinical Pipeline At Upcoming J.P. Morgan Presentation - PR Newswire 01.03.13 | 07:01 am
- AstraZeneca Announces Top-Line Results Of OSKIRA-4 Phase IIb Study Of Fostamatinib As A Monotherapy For Rheumatoid Arthritis - PR Newswire 12.13.12 | 07:12 am
- Rigel To Present At Jefferies 2012 Global Healthcare Conference In London - PR Newswire 11.08.12 | 07:11 am
- Rigel Announces Pricing Of Public Offering Of Common Stock - PR Newswire 10.03.12 | 09:10 am
- Rigel Announces Proposed Public Offering Of Common Stock - PR Newswire 10.02.12 | 04:10 pm
- Rigel To Present At UBS Global Life Sciences Conference - PR Newswire 09.17.12 | 07:09 am
- Rigel Initiates Phase 2 Clinical Studies With R343 For Asthma And R333 For Discoid Lupus - PR Newswire 09.05.12 | 07:09 am
- AstraZeneca And Rigel Sign Worldwide License Agreement For A Potential New Treatment For Chronic Asthma - PR Newswire 06.19.12 | 08:06 am
Partner Headlines for RIGL
- Today's Market News To Trade On: 5 Stocks Moving On News - Seeking Alpha 12.14.12 | 08:12 am
- Harley Davidson OPTIMISM and 4 Analyst Notes Making Rounds Now - Wall St. Cheat Sheet 07.02.12 | 03:07 am
- Rigel Refuels R&D in $130M Offering - Seeking Alpha 05.29.11 | 08:05 am
- CORRECTED - CORRECTED-BRIEF-Rigel earns $25 million from Astrazeneca - Reuters 09.29.10 | 07:09 am
- AstraZeneca signs arthritis drug deal - Financial Times 02.16.10 | 06:02 pm
- Rigel sees partner for psoriasis drug in 3 months - COO - Reuters 02.16.10 | 03:02 pm
